Cardinal Health’s Pharma Chief Sold 7,354 Shares and Still Grew Her Stake by 47%. Here’s How That Happened
Deborah Weitzman, CEO of the PSS Segment, reported a sale of 7,354 shares of Cardinal Health, Inc. (CAH +0.46%) in a recent SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | ~$1.7 million |
| Shares sold | 7,354 |
| Post-transaction shares (directly held) | 77,901 |
| Post-transaction value | ~$18.31 million |
Transaction value based on SEC Form 4 weighted average sale price ($235.45); post-transaction value based on the August 18 market close ($234.98).
Key questions
- How does this liquidation impact the insider’s equity position?
The sale of 7,354 shares reduced Weitzman’s direct stake by 9%, leaving the executive with 77,901 direct shares valued at $18.31 million as of the August 18 transaction date close. - What were the specific execution details of the trade?
The shares were disposed of at a weighted average price of $235.45, though individual execution prices ranged from $235.17 to $237.63 across multiple transactions. - What is the broader financial context for Cardinal Health at the time of this filing?
As of the August 19 market close, shares were priced at $234.85, supporting a market capitalization of $55.0 billion for the Dublin-based firm, which reported trailing twelve-month revenue of $254.2 billion.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-08-19) | $234.85 |
| Market Capitalization | $55.0 billion |
| Revenue (TTM) | $254.2 billion |
| Net Income (TTM) | $1.7 billion |
Company Snapshot
- Cardinal Health operates as a global integrated provider of healthcare products and services, delivering pharmaceutical distribution, medical products, and healthcare services across the United States, Canada, Europe, Asia, and other international markets.
- The company generates revenue through its two core divisions–Pharmaceutical and Medical–which provide distribution, logistics, and value-added services to hospitals, healthcare networks, pharmacies, outpatient surgical centers, clinical labs, and physician practices.
- Cardinal Health serves a diverse customer base, including healthcare providers, hospital systems, retail and specialty pharmacies, outpatient surgical centers, clinical laboratories, and physician practices, with additional reach into home healthcare and patient populations.
Cardinal Health is one of the largest healthcare services and products companies globally, with a TTM revenue base of $254.2 billion and a market capitalization of $55.0 billion. The company maintains a competitive advantage through its integrated distribution network, scale across pharmaceutical and medical segments, and established relationships with a broad spectrum of healthcare providers across multiple geographies. With 58,788 employees worldwide, Cardinal Health is positioned as a critical infrastructure provider within the healthcare supply chain, supporting the delivery of care across institutional and individual patient settings.
What this transaction means for investors
Weitzman sold 7,354 shares and still finished August owning far more Cardinal stock than she did at the start of it. She held 52,877 shares before performance units landed on Aug. 4, and 77,901 once the dust settled, an increase of about 47%. The CEO, CFO, legal chief and CIO all came out of the same window roughly flat or down, so she’s the one who took the award and mostly kept it.
Meanwhile, and importantly for long-term investors, Weitzman runs the segment that carried the quarter. Pharmaceutical and Specialty Solutions brought in $58.8 billion of revenue in the fourth quarter, up 6%, and segment profit rose 21% to $645 million. Specialty grew more than 25% across fiscal 2026. CEO Jason Hollar told analysts the company still sees “fantastic growth in our Biopharma Solutions business.” For fiscal 2027, segment revenue is guided to 3% to 5% growth and profit to 8% to 11%, with 2 to 3 points of that profit coming from acquisitions already announced. CFO Aaron Alt said first-quarter profit growth should run near the top of the range before the Solaris deal laps in the second quarter, which is when the organic number gets its first clean look.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
